Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feb. 1, Vol. 25, No. 3

    • Feature Articles

      • Advances in Microgenomics: Less is More
      • Once considered a limitation, small cell samples have now led to new technology advances that are providing researchers with faster and more accurate molecular information. These advances include separation methods to obtain pure cell populations, n ... more »
      • Antibody Therapeutics Dominate Meeting
      • Recombinant antibody therapeutics are moving to a next generation of products, according to a keynote address by Ronald Levy, M.D., given at IBC's recent meeting held in San Diego, "Antibody Engineering and Therapeutics." Dr. Levy is ... more »
      • Atlanta Bioscience Breaks into the Top Ten
      • The Atlanta metropolitan region ranks third nationally for the number of Fortune 500 companies headquartered there. Additionally, several medical organizations, such as the Centers for Disease Control and Prevention (CDC), the American Cancer Societ ... more »
      • Could London Become a Major Biotech Hub?
      • London's proximity to world-class universities providing high quality research and a thriving community of financial experts makes it an ideal place for biotech companies to locate, stated Jo Valentine, CEO of the business campaign group, London ... more »
      • High Throughput Screening of GPCRs
      • Kathy Liszewski
      • More than 50% of all current drugs and nearly 25% of the top 200 best-selling drugs target G-protein-coupled receptors (GPCRs).These heterotrimeric proteins contain seven membrane-spanning segments and consist of α, β, and γ subunits. To add to the ... more »
    • Legal Affairs

      • The Impact of Biotech Licensing
      • Biotechnology companies at all stages of growth need a robust technology platform and capital. StartUpCo, a hypothetical emerging biotech company, needs a technology platform and instant credibility to attract investors. Typically, StartUpCo looks t ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »